FindTrial
Sign In

Use of Advanced Ultrasound in treatment of Breast cancer.

Value of Shear Wave Elastography (SWE) in predicting response to Neo adjuvant chemotherapy (NACT) in different molecular subtypes of Breast cancer. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065044
Enrollment
49
Registered
2024-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Neha S Hubli
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All breast cancer patients planned for surgical excision after undergoing neo adjuvant chemotherapy (NACT).

Exclusion criteria

Exclusion criteria: Patients scheduled for upfront surgery or not planned for surgery post full course of NACT. Patients with recurrent/ metastatic breast cancer. Patient with loss to follow up due to change of primary care hospital or treatment discontinuation or death.

Design outcomes

Primary

MeasureTime frame
Response to NACT: Yes/No (Based on post-surgical HPE)Timepoint: 20-24 weeks post 1st cycle of NACT or 2-3 weeks post surgical resection of tumor—

Secondary

MeasureTime frame
Shear wave elastography parameter(s) that showed significance & their recommended cutoffs. Comparison of clinicopathological features & treatment regimen with respect to SWE parameters in responders & non-responders.Timepoint: 31st March 2026 or at end point of entire study—

Countries

India

Contacts

Public ContactDr Prakashini

Kasturba Medical college, MAHE, Manipal

docprakashinik@yahoo.co.in9845053325

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026